Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.12.6455

Altered Distribution and Expression Pattern of E-cadherin in Hepatocellular Carcinomas: Correlations with Prognosis and Clinical Features  

Jiang, Xue-Mei (Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education)
Zhang, Ju-Bo (Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education)
Xiong, Ju (Liver Cancer Institute, Zhongshan Hospital, Fudan University)
Huang, Xiao-Xi (Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education)
Ren, Zheng-Gang (Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.12, 2012 , pp. 6455-6461 More about this Journal
Abstract
Objective: E-cadherin has been identified as a tumor suppressor in many types of carcinoma. However, some studies recently suggested that the role and expression of E-cadherin might be more complex and diverse. In the present study, we evaluated the prognostic value of E-cadherin expression with reference to levels in membranes and cytoplasm, and the membrane/cytoplasm ratio, in hepatocellular carcinomas (HCCs) after curative hepatectomy. Methods: The expression of E-cadherin was assessed by immunohistochemistry in HCC tissue microarrays from 125 patients, and its prognostic values and other clinicopathlogical data were retrospectively analyzed. Patients were followed for a median period of 43.7 months (range 1 to 126 months). Results: Univariate analysis demonstrated that a high membrane/cytoplasm (M/C) ratio of E-cadherin expression was associated with poor overall survival (OS) (P =0.001) and shorter time to recurrence (TTR) (P=0.038), as well as tumor size, intrahepatic metastasis, and TNM stage. In contrast, neither membrane nor cytoplasmic expression of E-cadherin was related with OS and TTR. Furthermore, multivariate analysis confirmed the M/C ratio to be an independent predictor of OS (P=0.031). ${\chi}^2$ tests additionally showed that the M/C ratio of E-cadherin expression was related with early stage recurrence (P=0.012), rather than later stage recurrence. Conclusion: The M/C ratio of E-cadherin expression is a strong predictor of postoperative survival and is associated with early stage recurrence in patients with HCC.
Keywords
Hepatocellular carcinoma; E-cadherin; tumor suppressor;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Tang ZY, Ye SL, Liu YK, et al (2004). A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol, 130, 187-96.   DOI   ScienceOn
2 Thiery JP (2002). Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer, 2, 442-54.   DOI   ScienceOn
3 Wei Y, Van Nhieu JT, Prigent S, et al (2002). Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features. Hepatology, 36, 692-701.
4 Wijnhoven BP, Pignatelli M (1999) E-cadherin-catenin: more than a "sticky" molecular complex. Lancet, 354, 356-7.   DOI   ScienceOn
5 Wong AS, Gumbiner BM (2003). Adhesion-independent mechanism for suppression of tumor cell invasion by E-cadherin. J Cell Biol, 161, 1191-203.   DOI   ScienceOn
6 Xu HX, Zhu XD, Zhuang PY, et al (2011). Expression and prognostic significance of placental growth factor in hepatocellular carcinoma and peritumoral liver tissue. Int J Cancer, 128, 1559-69.   DOI   ScienceOn
7 Han AC, Peralta-Soler A, Knudsen KA, et al (1997). Differential expression of N-cadherin in pleural mesotheliomas and E-cadherin in lung adenocarcinomas in formalin-fixed, paraffin-embedded tissues. Hum Pathol, 28, 641-5.   DOI   ScienceOn
8 Ikeda K, Arase Y, Kobayashi M, et al (2003). Significance of multicentric cancer recurrence after potentially curative ablation of hepatocellular carcinoma: a longterm cohort study of 892 patients with viral cirrhosis. J Gastroenterol, 38, 865-76.   DOI   ScienceOn
9 Jiang WG, Mansel RE (2000). E-cadherin complex and its abnormalities in human breast cancer. Surg Oncol, 9, 151-71.   DOI   ScienceOn
10 Kavgaci H, Yildiz B, Fidan E, et al (2010). The effects of E-cadherin and bcl-2 on prognosis in patients with breast cancer. Bratisl Lek Listy, 111, 493-7.
11 Kensler TW, Qian GS, Chen JG, Groopman JD (2003). Translational strategies for cancer prevention in liver. Nat Rev Cancer, 3, 321-9.   DOI   ScienceOn
12 Lewis-Tuffin LJ, Rodriguez F, Giannini C, et al (2010). Misregulated E-cadherin expression associated with an aggressive brain tumor phenotype. PLoS One, 5, e13665.   DOI
13 Mayer B, Johnson JP, Leitl F, et al (1993). E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res, 53, 1690-5.
14 Montserrat N, Gallardo A, Escuin D, et al (2011). Repression of E-cadherin by SNAIL, ZEB1, and TWIST in invasive ductal carcinomas of the breast: a cooperative effort? Hum Pathol, 42, 103-10.   DOI   ScienceOn
15 Mosesson Y, Mills GB, Yarden Y (2008). Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer, 8, 835-50.   DOI   ScienceOn
16 Poon RT, Fan ST, Ng IO, et al (2000). Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer, 89, 500-7.   DOI   ScienceOn
17 Shim HS, Yoon BS, Cho NH (2009). Prognostic significance of paired epithelial cell adhesion molecule and E-cadherin in ovarian serous carcinoma. Hum Pathol, 40, 693-8.   DOI   ScienceOn
18 Qian YB, Zhang JB, Wu WZ, et al (2006). P48 is a predictive marker for outcome of postoperative interferon-alpha treatment in patients with hepatitis B virus infection-related hepatocellular carcinoma. Cancer, 107, 1562-9.   DOI   ScienceOn
19 Regimbeau JM, Abdalla EK, Vauthey JN, et al (2004). Risk factors for early death due to recurrence after liver resection for hepatocellular carcinoma: results of a multicenter study. J Surg Oncol, 85, 36-41.   DOI   ScienceOn
20 Ross JS, del Rosario AD, Figge HL, et al (1995). E-cadherin expression in papillary transitional cell carcinoma of the urinary bladder. Hum Pathol, 26, 940-4.   DOI   ScienceOn
21 Shirabe K, Kanematsu T, Matsumata T, et al (1991). Factors linked to early recurrence of small hepatocellular carcinoma after hepatectomy: univariate and multivariate analyses. Hepatology, 14, 802-5.   DOI
22 Sobin LH (2002). TNM classification of malignant tumors, 6th edn. Geneva, Switzerland: International Union Against Cancer.
23 Arulanandam R, Vultur A, Cao J, et al (2009). Cadherin-cadherin engagement promotes cell survival via Rac1/Cdc42 and signal transducer and activator of transcription-3. Mol Cancer Res, 7, 1310-27.   DOI   ScienceOn
24 Brunt EM (2000). Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology, 31, 241-6.   DOI   ScienceOn
25 Bussemakers MJ, van Bokhoven A, Mees SG, Kemler R, Schalken JA (1993). Molecular cloning and characterization of the human E-cadherin cDNA. Mol Biol Rep, 17, 123-8.   DOI   ScienceOn
26 Du GS, Wang JM, Lu JX, et al (2009). Expression of P-aPKCiota, E-cadherin, and beta-catenin related to invasion and metastasis in hepatocellular carcinoma. Ann Surg Oncol, 16, 1578-86.   DOI   ScienceOn
27 Cespedes MV, Larriba MJ, Pavon MA, et al (2010). Sitedependent E-cadherin cleavage and nuclear translocation in a metastatic colorectal cancer model. Am J Pathol 177: 2067-2079.   DOI   ScienceOn
28 Comoglio PM, Boccaccio C, Trusolino L (2003). Interactions between growth factor receptors and adhesion molecules: breaking the rules. Curr Opin Cell Biol, 15, 565-71.   DOI   ScienceOn
29 Cowin P, Rowlands TM, Hatsell SJ (2005). Cadherins and catenins in breast cancer. Curr Opin Cell Biol, 17, 499-508.   DOI   ScienceOn
30 Fransvea E, Angelotti U, Antonaci S, Giannelli G (2008). Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology, 47, 1557-66.   DOI   ScienceOn
31 Garcia S, Martini F, De Micco C, et al (1998). [Prognostic value of E-cadherin expression in hepatocellular carcinoma]. Ann Pathol, 18, 98-102.